All In Biotech

NDA 021162 · Boehringer Ingelheim

Micardis Hct

Hydrochlorothiazide, Telmisartan · Oral · Thiazide Diuretic; Angiotensin 2 Receptor Blocker

Last checked: Nov 20, 2026Latest source record: Dec 19, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Nov 17, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

450

138 Phase 3, 14 recruiting

FAERS reports

2,358

1,474 serious, 145 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue MICARDIS HCT as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning . When pregnancy is detected, discontinue MICARDIS HCT as soon as possible. ( 5.1 , 8.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 , 8.1 )

What it is approved for

From the label in effect Dec 31, 2024.

MICARDIS HCT (telmisartan and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with MICARDIS HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at...

Mechanism: MICARDIS HCT MICARDIS HCT is a combination of two drugs with antihypertensive properties: a thiazide diuretic, hydrochlorothiazide, and an angiotensin II receptor blocker (ARB), telmisartan. Telmisartan Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan blocks the vasoconstrictor and...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • MICARDIS HCT · HYDROCHLOROTHIAZIDE 12.5MG; TELMISARTAN 80MG · TABLET, ORAL · Prescription · TE AB
  • MICARDIS HCT · HYDROCHLOROTHIAZIDE 25MG; TELMISARTAN 80MG · TABLET, ORAL · Prescription · TE AB
  • MICARDIS HCT · HYDROCHLOROTHIAZIDE 12.5MG; TELMISARTAN 40MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydrochlorothiazide" as an intervention, any sponsor and status, largest first.

All 450 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness152
  • drug ineffective120
  • nausea118
  • fatigue112
  • headache111
  • blood pressure increased105
  • diarrhoea96
  • dyspnoea93
  • hypotension84
  • hypertension83
  • fall81
  • vomiting79

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200448
200558
200680
2007132
2008189
2009186
2010243
2011245
2012218
2013104
2014100
201597
2016101
201780
201888
201976
202066
202151
202230
202339
202434
202563
202630

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Micardis HCT (Telmisartan/Hydrochlorothiazid)

2024 spending

$786K

Beneficiaries

614

2,874 claims

Per beneficiary

$1,280

$4.42 per unit

View as table
YearSpending
2020$2,049,026
2021$1,753,716
2022$1,082,482
2023$947,481
2024$786,047

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,366 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.